What is the efficacy of the combination of everolimus/Afinitor and voronib?

Everolimus (Everolimus) is a targeted drug widely used in cancer treatment, especially in the treatment of renal cell carcinoma, breast cancer and some neuroendocrine tumors. Vorolanib (Vorolanib) is a newer anti-tumor drug, mainly used for the treatment of malignant tumors such as renal cell carcinoma. In recent years, clinical studies of the combination therapy of everolimus and voronib in advanced renal cell carcinoma (RCC) have received relatively positive reviews, especially in the treatment of patients with advanced renal cell carcinoma who have failed previous tyrosine kinase inhibitor treatment, showing good efficacy.

Everolimus inhibits the proliferation and growth of tumor cells by inhibiting themTOR pathway, while voronib, as a multi-target tyrosine kinase inhibitor, can inhibit targets related to tumor angiogenesis, help control the blood supply of tumors, and further slow down the development of tumors. The combined use of these two drugs can theoretically interfere with the proliferation and metastasis of tumor cells from two different angles, thus improving the therapeutic effect.

Everolimus in combination with voronib has become a common treatment option in China, especially in patients with advanced renal cell carcinoma who are resistant to traditional targeted therapies such as sunitinib and sorafenib. Clinical studies have shown that the combined use of everolimus and voronib can effectively delay tumor progression and significantly improve the overall survival of patients. The combined treatment is well tolerated and the side effects are relatively controllable.

However, although combination therapy has its positive clinical prospects, the specific therapeutic effects still vary depending on individual differences among patients. Some patients may experience drug-related side effects, such as oral ulcers, liver damage, etc. Therefore, when using combination therapy, the patient's health status needs to be closely monitored and the treatment plan adjusted based on clinical response.

Reference: https://db.yaozh.com/instruct/5511237633449984.html